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The number of female cancer survivors has been rising rapidly. We assessed the occurrence of breast cancer in these survivors over
time. We computed incidence of primary breast cancer in two cohorts of female cancer survivors with a first diagnosis of cancer at
ages 30þ in the periods 1975–1979 and 1990–1994. Cohorts were followed for 10 years through a population-based cancer
registry. Over a period of 15 years, the incidence rate of breast cancer among female cancer survivors increased by 30% (age-
standardised rate ratio (RR-adj): 1.30; 95% CI: 1.03–1.68). The increase was significant for non-breast cancer survivors (RR-adj: 1.41,
95% CI: 1.04–2.75). During the study period, the rate of second breast cancer stage II tripled (RR-adj: 3.10, 95% CI: 1.73–5.78). Non-
breast cancer survivors had a significantly (P value¼0.005) more unfavourable stage distribution (62% stage II and III) than breast
cancer survivors (32% stage II and III). A marked rise in breast cancer incidence among female cancer survivors was observed.
Research to optimise follow-up strategies for these women to detect breast cancer at an early stage is warranted.
British Journal of Cancer (2009) 100, 77–81. doi:10.1038/sj.bjc.6604816 www.bjcancer.com
Published online 9 December 2008
& 2009 Cancer Research UK
Keywords: female survivors; second primary cancer; breast neoplasm; trend
                                         
Breast cancer is the most common cancer among women in
general, but also among women who were previously diagnosed
with any type of cancer (Mariotto et al, 2007). During the past
three decades, a fourfold increase in the incidence of contralateral
breast cancer has been reported, which is much higher than that of
first primaries (Louwman et al, 2008). However, in the same
period, a 9% decrease in the incidence of second breast cancer
among former breast cancer patients was reported in the United
States of America (Yu et al, 2006). The increasing prevalence of
patients ever diagnosed with cancer should theoretically result in
an increase in the incidence of new primary cancer (Fraumeni
et al, 2006), that is, breast cancer among cancer survivors. Changes
in female reproductive behaviour and lifestyle, that underlie the
increasing trend of first breast cancer, may also affect the increased
risk of a second breast cancer (Dignam et al, 2003; Largent et al,
2007). Furthermore, cancer survivors are exposed to additional
carcinogenic factors such as high-dose radiation for the first
cancer (van Leeuwen and Travis, 2005). Using data from a long-
standing cancer registry in southern Netherlands, we investigated
the incidence of breast cancer among cancer survivors since 1975.
We assessed the change in incidence of a second breast cancer over
time according to age, stage and type of treatment of the first
cancer.
MATERIALS AND METHODS
Data on cancer patients were obtained from the Eindhoven Cancer
Registry (ECR), located in the south of Netherlands. This is a
population-based registry with follow-up data since 1970, includ-
ing clinical aspects such as stage and initial treatment. The cancer
registry regularly receives lists of new cancer cases from the
pathology and haematology departments in the region. In addition,
lists of all hospitalised cancer patients were obtained, comprising
data from hospital medical records. In the ECR, active follow-up of
vital status is conducted through linkage with municipal popu-
lation registries and the Central Bureau for Genealogy. Eindhoven
Cancer Registry is a long-standing cancer registry with high-
quality data, as indicated by the high proportion of histologically
verified cases. (Curado et al, 2007) Furthermore, the proportion of
new cases identified through death certificates or autopsy only is
0%, indicating efficient case finding (Curado et al, 2007). The
coverage area of the registry in the south of the Netherlands has
gradually increased, covering about 0.9 million people between
1975 and 1985 and over 2 million people since 1988.
Data analysis
The change in breast cancer incidence among cancer survivors
over time was calculated using the fixed inception cohort method
(Yu et al, 2006). We defined two patient cohorts: women diagnosed
with a primary cancer between 1975 and 1979 and those diagnosed
between 1990 and 1994. We included all cancer types diagnosed in
women aged 30 years or more within the given periods, excluding
premalignant or in situ cancer and basal cell carcinoma of the skin.
Only patients who survived 6 months or longer were included in
the cohort. The rules for multiple primary cancers from the
International Agency for Cancer Research were used (Working
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sGroup Report, 2005). Based on these rules, a person can have only
one cancer per organ or pair of organs except when multiple
tumours within an organ have a different histology. For breast
cancer, two tumours of different laterality but of the same
morphology are registered separately (2005). The follow-up time
extended from the date of the initial cancer diagnosis to the date of
a second cancer, death, loss to follow-up or end of the study,
whichever occurred first. We applied a 10-year follow-up for each
patient cohort. Thus, the 1975–1979 cohort was followed until
1989 and the 1990–1994 cohort until 2004. Person-years
contributed by each survivor were calculated to compute incidence
rates per 100000 person-years. Adjustment for age was performed
by calculating predicted rates of expected new breast cancer
incident cases, assuming identical age composition (entered in 5-
year age categories) of the first and second cohort. We used
Poisson regression using Proc genmod in SAS. To compare the two
periods, rate ratios of breast cancer and their 95% confidence
intervals (95% CI) were computed taking the earlier cohort (those
diagnosed with first cancer between 1975–1979) as reference
(Breslow and Day, 1987).
To identify the factors causing differences in rates over time, we
stratified according to type of first primary cancer (breast and
non-breast cancer) and treatment of the first primary (surgery,
radiotherapy with or without surgery, systemic therapy with or
without surgery, radiotherapy and systemic therapy with or
without surgery and no therapy).
Finally, incidence rates of breast cancer in female survivors
were calculated stratifying by age (30–49 years, 50–74 years and
75þ years) and TNM-stage (Sobin and Fleming, 1997). This
provides insight on the role of breast cancer screening in trends of
breast cancer among survivors.
RESULTS
Within 10 years of the first cancer diagnosis, 100 of 3368 (3%) and
182 of 5507 (3%) female cancer survivors diagnosed in the 1970s
and in the 1990s, respectively, were subsequently diagnosed with
breast cancer. Compared to patients diagnosed in the 1970s, cancer
survivors diagnosed with a first cancer in the 1990s were 2.1 years
older at first diagnosis and were more likely to have received
systematic treatment (combined with either surgery or radio-
therapy; Table 1). In both periods, digestive and urogenital cancers
were the most common first non-breast cancer tumours.
Compared with the first period, a 30% increase in breast cancer
incidence was observed in female cancer survivors (age-adjusted
rate ratio (RR-adj): 1.30; 95% CI: 1.03–1.68; Table 2). Most marked
increase in incidence of breast cancer was found among women
previously diagnosed with non-breast cancer (RR-adj: 1.41; 95% CI:
1.04–2.75). There appeared to be a similar increase in breast cancer
incidence across most treatment groups, albeit with wide confidence
intervals. After adjusting for age, treatment and type of first cancer,
the increase over time in breast cancer incidence among survivors
became larger (RR-adj: 1.42; 95% CI: 1.11–1.83). This corresponded
to a 201 excess cases per 100000 female cancer survivors.
Table 3 shows that the increase over time in the incidence of
breast cancer among female cancer survivors was similar for all age
groups. The incidence rate tripled for stage II breast cancer (RR-adj:
3.10; 95% CI: 1.73–5.78) between the late 1970s and the early 1990s.
Figure 1 illustrates the stage distribution of breast cancer for
female survivors diagnosed with a first cancer in 1990–1994
categorised according to age at second breast cancer diagnosis and
type of first cancer. A significant difference in stage distribution
was found for the non-breast cancer survivors compared to those
with a previous breast cancer. The proportion of second breast
cancer stages II and III among non-breast cancer survivors
was 62%, compared to only 32% among breast cancer survivors
(P value¼0.005).
DISCUSSION
In the general population, a 20% increase in the incidence of breast
cancer has been reported over a 15-year period. (Louwman et al,
2008) In the same period, we observed an increase of 30% in the
incidence of breast cancer among female cancer survivors. This
increase was largest for non-breast cancer survivors and for
second breast cancer stage II. The relatively large increase in breast
cancer incidence among cancer survivors may be due to several
factors: (1) The breast cancer early detection program (mass
screening) that started in the early 1990s in the Netherlands; (2)
application of more combined therapies with higher carcinogenic
potential and (3) lifestyle, reproductive and hormonal factors, such
as a longer interval between menarche and date of first birth, use of
hormonal replacement therapy and alcohol use.
In the early 1990s, biennial mass screening for breast cancer was
implemented for all women aged 50–69 years. In 1998, this
program was expanded to include women up to the age of 75
(Verbeek and Broeders, 2003). Due to the intensified use of
mammography for mass screening, the incidence of breast cancer
increased by about 30% (Fracheboud et al, 2004) and may thus
also be responsible for the increased incidence of breast cancer
among cancer survivors. Consistently, we observed a significant
increase in the proportion of female survivors diagnosed with early
breast cancer (stages I and II being 54% in 1970s vs 76% in 1990s).
On the other hand, we observed a similar increase in the incidence
of breast cancer among survivors that do not fall in the screening
age-target group (o50 and 474 years) to those targeted by
screening (50–74 years). Furthermore, the increase of breast
cancer incidence among female survivors is larger than that of the
general population. This suggests that screening cannot fully
account for this increase. Other breast cancer risk factors are likely
to have contributed to this increase, including older age at first
childbirth, fewer children, alcohol and other determinants of post-
menopausal obesity (Althuis et al, 2005).
Table 1 Characteristics of female cancer survivors diagnosed in 1975–
1979 and in 1990–1994 with a 10-year follow-up
Period of first primary cancer diagnosis 1975–1979 1990–1994
Number of cancer survivors 3368 5507
Women-years of follow-up 19287 26913
Mean age at first cancer (years) 60.5 62.7
Mean follow-up time (years) 5.7 4.9
N % N %
Age at diagnosis of first cancer
30–49 years 791 23 1200 22
50–74 years 2070 61 3086 56
75+ years 507 15 1221 22
Treatment of first cancer
Surgery 1417 42 2248 41
Radiotherapy±surgery 1245 37 1450 26
Systemic therapy±surgery 322 10 767 14
Radiotherapy+systemic therapy±surgery 220 6 760 14
No therapy 164 5 282 5
Type of first cancer
Breast cancer 1436 43 2199 40
Non-breast cancer
a 1932 57 3308 60
N indicates number of cases and % indicates column’s percentage.
aFirst non-breast
cancer in 1970s consisted of 3% respiratory cancers, 40% digestive cancers, 34%
urogenital cancers (of which 24% (155 cases) were ovarian cancer cases), 9%
haematopoietic cancers (Hodgkin lymphoma 19 cases) and 15% other cancers, and in
1990s 7% respiratory cancers, 33% digestive cancers, 30% urogenital cancers
(of which 24% (238 cases) were ovarian cancer cases), 10% haematopoietic cancers
(Hodgkin lymphoma 17 cases) and 19.3% other cancers.
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sIn the Netherlands, patients with breast cancer receive enhanced
surveillance: annual mammography until the age of 60, followed by
a biennial mammography up to the age of 74 (NABON Nationaal
Borstkanker Overleg Nederland, 2005). This intense surveillance
pattern is likely to explain the better stage distribution compared
with the non-breast cancer survivors. In addition, it may also
contribute to an increase in detection rates for slow-growing
tumours that would have remained in the pre-clinical phase longer
without screening mammography (Shen et al, 2005). Thus, breast
cancer survivors are probably diagnosed more often and earlier
with a low-grade breast cancer, which may require less aggressive
treatment than other cancers (Moody-Ayers et al, 2000).
Changes in therapy for first primary cancer may have influenced
the incidence of second breast cancer over time. Radiotherapy has
been associated with an approximately 40% higher risk of
developing subsequent breast cancer compared to systemic
hormonal or cytotoxic treatment (Soerjomataram et al, 2005;
Schaapveld et al, 2008). In addition, cancer patients who receive a
high radiation dose on the chest as part of treatment have higher
breast cancer risk. For example, young women with Hodgkin
lymphoma may have up to 29% cumulated risk of breast cancer 30
years after treatment. (Travis et al, 2005) On the other hand,
radiotherapy treatment techniques and protection of the normal
tissue have improved in the last decades. In our study, we observed
a similar increase in the incidence of breast cancer over time for
those who were irradiated and those who only underwent surgery.
The increasing incidence of breast cancer among those who were
irradiated could therefore not be attributed to radiotherapy.
However, because we followed patients for only 10 years, we may
have missed late adverse effects of radiation (Travis, 2006).
Table 2 Number (N) and age-standardised incidence rates of breast cancer per 100000 women-years for female cancer survivors
a
1970s 1990s
Period of first primary cancer diagnosis N Incidence (100000) N Incidence (100000) Rate ratio
b (95% CI)
Type of first primary cancer
c
Breast cancer 77 839 127 999 1.19 0.91–1.60
Non-breast cancer 23 228 55 387 1.41 1.04–2.75
Treatment of first primary cancer
c
Surgery 39 451 74 634 1.41 0.95–2.08
Radiotherapy±surgery 48 625 64 851 1.36 0.94–1.98
Systemic therapy±surgery 5 371 15 520 1.40 0.48–3.75
Radiotherapy+systemic therapy±surgery 7 702 25 613 0.87 0.39–2.10
No therapy 1 157 4 531 3.38 0.40–31.69
Incidence rates (only age adjusted)
c 100 519 182 676 1.30 1.03–1.68
Incidence rates (age, type of first cancer and treatment of first cancer adjusted) 100 475 182 676 1.42 1.11–1.83
N indicates number of cases.
aFemale cancer survivors are both breast cancer and non-breast cancer survivors.
bRate ratio compares incidence rate in 1990s with incidence rate
in 1970s.
cAge adjusted.
Table 3 Incidence rates of breast cancer per 100000 women-years for female cancer survivors
a according to age and stage of breast cancer (second
primary) in 1970s and 1990s
1970s 1990s
Period of first primary cancer diagnosis
60.8 63.2
Mean age at breast cancer (years) N Incidence (100000) N Incidence (100000) Rate ratio
b (95% CI)
Age at breast cancer (second primary – age-specific rates)
30–49 years 23 678 43 887 1.3 0.8–2.2
50–74 years 61 509 94 615 1.2 0.9–1.7
75+ 16 409 45 664 1.6 0.9–2.9
Stage of breast cancer (second primary)
c
I 41 209 82 305 1.46 0.99–2.11
II 13 68 57 212 3.10 1.73–5.78
III 11 58 18 67 1.16 0.56–2.50
IV 9 46 14 52 1.14 0.50–2.65
Unknown 26 140 11 41 0.29 0.14–0.59
N indicates number of cases.
aFemale cancer survivors are both breast cancer and non-breast cancer survivors.
bRate ratio compares incidence rate in 1990s with incidence rate
in 1970s, if adjusted rates are presented than rate ratio is based on the standardised rates.
cAge adjusted.
Breast,
30–74 years
Non-breast,
30–74 years
Breast,
75+ years
Non-breast,
75+ years
Type of the first cancer and age at the second breast cancer
100%
80%
60%
40%
20%
0%
Unknown
IV
III
II
I
Figure 1 Stage distribution of breast cancer in female cancer survivors
diagnosed with a first cancer in 1990–1994 according to type of first
cancer and age at (second) breast cancer diagnosis.
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sAlthough the use of systemic cancer treatment has doubled during
the last 20 years, we found that the increase in the incidence of
breast cancer among those who received systemic treatment was
similar to surgically treated patients, whereas a decrease in
incidence was expected. Studies have shown that cancer patients
who have hormonal therapy (eg tamoxifen) or chemotherapy have
a reduced risk of breast cancer (van Leeuwen et al, 2003; Early
Breast Cancer Trialists’ Collaborative_Group, 2005). A protective
effect of tamoxifen on second breast cancer is most evident in the
post-treatment period (Powles et al, 2007). Thus, it is possible that
changes in rates over time may differ for different categories of
follow-up, for example, decreasing trend of breast cancer in
survivors who received tamoxifen, which is only observable 8 years
after treatment. Unfortunately, we did not have sufficient power to
examine trends across different follow-up periods.
In view our results the following groups may need a more
intensive follow-up for breast cancer. Firstly, non-breast cancer
survivors. These patients had a larger proportion of stage II breast
cancer than patients who had breast cancer as a first primary
cancer. Among non-breast cancer patients diagnosed in 1990–
1994 and followed up for 10 years, 29% of second breast cancers
was stage 1, 44% stage 2, 18% stage III and 5% stage IV. For breast
cancer patients, the corresponding percentages were 52% for stage
I, 26% for stage II, 6% for stage III and 9% for stage IV (P value of
w
2: 0.005). Thus, although the absolute risks (2% during 10-year
follow-up) remain small, female survivors of non-breast cancer
would probably benefit from a more intensive follow-up than just
the mass-screening program, such as an additional biennial
clinical breast examination. (Rijnsburger et al, 2004) A second
group is female survivors older than 75 years. (Boer et al, 1995)
Survivors of this age group exhibited the largest increase in breast
cancer incidence over time. Furthermore, compared to the general
population, they had a threefold higher risk of breast cancer than
the general population. (Comprehensive_Cancer_Centre, 2007)
Given a worse stage distribution especially among those diagnosed
with a non-breast cancer, it seems logical to extend the screening
program to include older female survivors. However, mortality due
to other causes is high (Hooning et al, 2006) and the existence of
comorbidities would probably limit treatment choices. (Louwman
et al, 2005) Furthermore, early detection increases overdiagnosis
and may lead to overtreatment. In older women, this issue is
greater due to the longer sojourn time of breast cancer, that
is longer time in which a cancer is still asymptomatic, but already
detectable by a screening test. (Fracheboud et al, 2006) Thus, a
detailed cost-effectivity study, preferably adjusting for Quality of
Life, is warranted. A last group is cancer survivors younger than 50
years. Although the incidence of breast cancer has not increased
much over time, incidence was highest for survivors aged 30–49
years. This group may merit the same screening regimen as
women with a genetic predisposition towards breast cancer, that is
with an MRI.
It should be warranted that besides the apparent beneficial effect
that is detecting cancer at an early stage, screening has also
harmful effects. Therefore, a decision to screen should always
weigh the benefit, harm and cost. (Fracheboud et al, 2006) The
main unfavourable effect is overdiagnosis, that is diagnosis of
cancers that would not have been detected if there had not been
screening. This leads to a loss of quality of life, because the person
has to live with a cancer diagnosis and unnecessary treatment.
Furthermore, early detection using mammography may increase
the lifetime exposure to radiation and hence the breast cancer risk.
However, simulation studies have shown that screening prevented
more deaths from breast cancer than it induced. (Beemsterboer
et al, 1998).
In summary, we found a significant increase in the incidence of
breast cancer among female cancer survivors, especially for non-
breast cancer survivors. The increase in second breast cancers was
most striking for stage II cancers. Our findings suggest that there is
ample room for improvement in follow-up strategies to detect
breast cancer at an early stage in this group.
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